Participants 194 265 4
patients with unresectable stage IIIA and B non-small-cell lung cancer.
Participants 447 637 6
Eligible patients were treatment naive, and had stage IIIA and B unresectable non-small-cell lung cancer, Eastern Cooperative Oncology Group performance status 0/1, and normal organ function
Participants 890 1013 4
A total of 388 patients were needed to detect a 50% increase in median survival from 14 months of qdRT to 21 months of HART
Participants 1085 1107 6
141 patients enrolled,
Participants 1490 1561 3
14 v nine patients, and pneumonitis in 0 v 6 patients for HART and qdRT
